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Purpose:  The aim of our present work is the development of a quasi steady-state model for the 
distribution of intravitreally injected drugs and investigation of the effects of various model parameters 
on the drug distribution in normal and diseased eyes. 
Method: A simple mathematical model for the intravitreal transport of drugs was developed using Fick’s 
law of diffusion, Darcy’s law of convective flow, and Michaelis –Menten kinetics of metabolism. A Crank-
Nicolson finite difference scheme of the equation  describing the drug transport  in the vitreous body was 
written, in which the radial and axial diffusive terms and convective terms of the  equation were 
approximated by central differences, while the temporal terms were approximated by average of forward 
and backward time differences. A system of linear algebraic equations obtained from the Crank Nicolson 
finite difference scheme was solved by line Jacobi iterative scheme in which successive improved 
approximate results are obtained.  
Result:  The model predicts that an increase in the metabolic (consumption) rate and drug release rate 
constant reduces the concentration of intravitreally injected drug at the centre of retina and along 
centreline of vitreous body. A significant increase in the drug concentration at the centre of retina and 
along the centreline of the vitreous body in  the eye afflicted with glaucoma and retinal detachment is 
observed and the decay rate of drug concentration in these pathological states is higher than that in the 
normal eyes. 
Conclusion: The vitreous outflow as observed in the glaucomatous and/- or rhegmatogenous eyes may 
contribute to the transport of intravitreally injected drug in the vitreous body. The drug concentration in 
the vitreous body and at the centre of retina in such diseased eyes is higher than that in the normal eyes 
and the decay rate of drug concentration is significantly enhanced. 
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INTRODUCTION 
Several vitroretinal diseases such as 
cytomegalovirus retinitis, age- related macular 
degeneration (AMD), retinitis pigmentosa 
(R.P), diabetic retinopathy and a combination 
of similar retinal diseases are currently being 
treated by using drug intravitreal injection or 
control release implant of drugs1. The 
diffusion of drug, convection of vitreous 
outflow, enzymatic reaction (metabolism), 
drug binding and efficacy of delivery system 
mainly control the bioavailability of drug after 
its intravitreal injection and controlled release 
implant. Many drugs used to treat vitreoretinal 
diseases have a narrow concentration range 
in which they are effective and may be toxic at 
higher concentrations 2, 3. Therefore, it is 
critical to know the drug distribution within the 
vitreous following delivery by intravitreal 
injection or controlled release implant. The 
ability to predict drug distribution can 
maximize the therapeutic benefits and 
minimize potential adverse effect such as 
possible tissue damage caused by 
excessively high concentrations of drug. A 
mathematical analysis of the drug 
concentration and theoretical investigation of 
the effects of physiological parameters on the 
concentration may elucidate the mechanism 
of drug transport in the vitreous and may 
contribute to the improvement of present 
understanding of the bioavailability of drugs 
required for the treatment of vitroretinal 
diseases. 
 Several studies4, 5, 6 ,7 have analyzed 
intravitreal drug distribution and the 
elimination of drug from the vitreous of the 
eye. Previous studies6, 8 have assumed that 
the vitreous humor was stagnant, ignoring 
convective drug transport within the vitreous 
body. It is well known that during the 
pathogenesis of glaucoma, intraocular 
pressure (IOP) is elevated (40-80 mm Hg) due 
to the obstruction of the aqueous outflow 
system which may increase the flow of 
aqueous humor through the vitreous. Under 
extreme pathophysiologic conditions, e.g 
rhegmatogenous retinal detachment, the 
integrity of the retina is broken, allowing 
vitreous outflow to pass into the subretinal 
space. The rate of fluid movement through a 
retinal tear was estimated to be 1.2 µL/min9, 
signifying a ten-fold increase and a maximum 
condition for elevated flow, when compared to 
normal vitreous outflow of 0.1 µL/min10.This 
increase in the vitreous outflow   may be 
caused by the enhanced hydraulic 
conductivity of the retina. Thus, the vitreous 
outflow can play a significant role in drug 
distribution in glaucomatous or 
rhegmatogenous retinal detached eyes.  
Stay MS. et al 6 developed a mathematical 
model for prediction of the biodistribution of 
drug in the vitreous body released from 
injectable biodegradable polymer 
microspheres. They considered the diffusive 
and convective mass transport of drug within 
the vitreous and neglected the metabolic 
consumption and degradation of drug in 
vitreous body. Kakuji 11 has also presented a 
pharmacokinetic model for ocular drug 
delivery in the spherical modified cylindrical 
eye based on Fick’s law of diffusion but 
neglected the convective transport.  
The present work is concerned with the 
development of a simple mathematical model 
for the quasi-steady state concentration 
distribution of drug in the viteous body. The 
objective of the present work was to 
investigate the effects of the parameters 
metabolic rate and intraocular pressure on the 
drug concentration distribution of the 
intravitreally injected drugs and on change in 
drug concentration with time at the centre of 
retina. Besides the some other physiological 
parameters on the drug concentration also 
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where m, B are the reaction rate and Michaelis Menten rate constants, respectively, for the metabolic 
process in the vitreous body. In the present study, the metabolic and degradation of drug is 
approximated by a first order metabolic rate constant in the vitreous body for intravitreal injection. The 








































where M is the  initial loading of the drug (kg), 1K )(sec
1−  the  release rate constant of the drug, 
and V the volume of the drug injected )( 3m .The release term is defined only at the injection site and 
is zero for all other positions within the vitreous body. 
Now, Eq. (1) can be written in the form: 
 





                   
….(5) 
where k  is the  permeability  of the vitreous body, µ , the  viscosity  of the permeating  aqueous 
humor, and p, the fluid  pressure  in the vitreous body. A  ratio 
µ
k
 is termed as the hydraulic 
conductivity of vitreous body.  
Using continuity equation 0. =∇ v  ,we get: 
 
                                                               02 =∇ p  ….(6) 
where,
2∇  is the Laplacian  operator in a cylindrical co-ordinate system. 
Boundary Conditions for Pressure: The physiologically relevant and mathematically consistent boundary 






































where, rk  the hydraulic conductivity of the retina , pk the hydraulic conductivity of posterior chamber –vitreous 
body interface , p the fluid pressure in the vitreous body, thepv ,  pressure of the vein downstream flow, and 
ap ,the intraocular pressure.  Initial Condition for Concentration: For the intravitreal injection of drug, the 
initial condition is described as follows:     
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     c(r,z,0) =      co,    inside the hypothetical cylindrical cavity           ….(9) 
                                  0,     outside the cylindrical cavity                  
 
 Boundary Conditions for Concentration: The boundary conditions for the drug 
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Where c is the drug concentration in the vitreous body,bo the effective radius of lens.The subscripts p,l,r refer to 
as the posterior chamber membrane, posterior lens surface  and the RCS membrane, respectively.   
Solution  to the model. The analytical solution to Eq. 6 subject to the boundary conditions 8(a,b)-10(a,b)  is 
given by : 
][)]([),( 2220
zkzk eHGerkJCzrp +=   0 0br ≤≤  …..(14) 
][)]([),( 33 1130
zkzk eHeGrkJCzrp +=  Rrb ≤≤0  ......(15)  
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where nz  are the  possible zeros of the Bessel function. 
The approximate steady-state distributions of radial and axial velocities were computed and use in numerical 
solution of the mathematical model. 
Numerical Solution to the Model: A numerical solution of the partial differential equation governing the quasi-
steady state distribution of drug in the vitreous body is obtained by using d in numerical solution of the 
mathematical model. the implicit Crank-Nicolson scheme16. The finite difference analogue of Eq.4, obtained by 
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Figure 1: Schematic diagram showing the interrelationship of the various compartments of the eye.10 
Diffusive drug is released at the center of the cavity (vitreous chamber) and the injected fluid has a 
homogenous distribution within a cylindrical region. The drug elimination in the vitreous body is 
assumed to occur across three different diffusion-convection routes of the eye: the posterior chamber, 




Figure 2: Schematic representation of cylindrical vitreous body model 12. R: radius of vitreous body, H: height 
of vitreous body, r: radial distance, z: axial distance, 0b :effective radius of lens respectively. 
The concentration of a drug in the vitreous body is described by the partial differential equation which 

































where c is the concentration of drug in the vitreous body, D the diffusion coefficient of  drug, R(r,z,t) the 
metabolism and degradation rate, B(r,z,t ) drug binding term and ),,( tzrqc  release rate of  injected drug. 
Effect of drug binding in the drug concentration is negligible compared to that of convection, diffusion and 
metabolism of drug. The metabolism    and degradation of drug in the vitreous body is assumed to follow    









where m, B are the reaction rate and Michaelis Menten rate constants, respectively, for the metabolic 
process in the vitreous body. In the present study, the metabolic and degradation of drug is approximated 
by a first order metabolic rate constant in the vitreous body for intravitreal injection. The delivery of drug at 
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The almost spherical vitreous body Fig.(1) is 
represented as a porous fluid filled cylinder in 
contacts with the retina/choroids membrane, 
the lens posterior capsule (chamber), and the 
posterior aqueous humor Fig.(2). A 
hypothetical cylindrical cavity is assumed 
placed on the axis of symmetry behind the 
lens in the vitreous body. We assume that the 
diffusion of drug and moving liquid will 
originate in this cavity.   
The implicit iterative scheme given by Eq.16 is 
simplified in the light of finite difference  
analogues of the initial and boundary 
conditions 10-13(b) and  the resulting system 
of algebraic equations written in the 
pentadiagonal  matrix form 
)( ,,1,, kjikji cfcA =+  was  solved by the line-
Jacobi iterative technique. Computations were 
conducted and post processed on a 
COMPAQ-PC, Intel Pentium IV 2.40 GHz 
processor, with 1.0 GB of RAM, and 80 GB 
hard disk. The results were plotted in Excel. 
 
RESULTS 
The computational results of the present 
model have been obtained by solving the 
system of algebraic equations obtained from 
Eq.16 along with Eq.17 and using estimated  
values of the physiological parameters listed 
in Table.1.  The concentration plot of the drug 
at the centre of retinal surface with respect to 
time and effects of various model parameters 
on the concentration change with time have 
been displayed in Fig.3(a)-(e). It is observed 
from curves that the drug concentration 
increases with time in initial hours after 
intravitreal injection.  The concentration of   
high diffusivity drugs is lower than that of low 
diffusivity drugs in initial hours. After 100 
hours the concentration of high diffusivity 
drugs becomes higher than that of low 
diffusivity drugs. As is evident from the graphs 
in Fig.3(b) an increase in the metabolic 
reaction rate decreases the drug  
concentration  at the centre of retina. This is 
true because when the value of metabolic 
reaction rate is increased, more amount of 
drug will be consumed and degraded leading 
to a decrease in the drug concentration at the 
centre of retina. The drug concentration 
change with time is influenced by the rate of 
drug delivery. 
 
DISCUSSION   
The concentration distribution of intravitreally 
injected drug and the change in drug 
concentration with time at the centre of retina 
are relevant for treatment of some vitro-retinal 
diseases such as, age-related macular 
degeneration (AMD), retinitis pigmentosa, 
glaucoma, rhegmatogenous  retinal 
detachment etc. The present analysis has 
been primarily concerned with the theoretical 
investigations of independent effects of the 
intraocular pressure and metabolic 
consumption of drug on the concentration 
distribution in the vitreous body and time- 
variation in the concentration of low and high 
diffusivity drugs at the centre of retina. As has 
been observed a rise in the intraocular 
pressure and a retarded metabolic 
consumption causes an increase in the drug 
concentration and concentration change at the 
retinal surface. Some future experimental 
studies must be directed towards the 
investigations of such effects and focus on the 
similar analysis. 
The present analysis has been concerned 
with the investigation of independent effects of 
various model parameters on the drug 
concentration. But in practical situations these 
parameters will interact and there should be a 
consideration for the interactive effects. For 
the purpose, future studies in this field should 
try to propose and establish relationships 
among/ between model parameters. However 
the interactive effects of the parameters can 
be observed by using different sets of values 
of model parameters of interest. 
The mathematical model proposed in this 
study will be a useful approach for predicting 
the drug availability and its elimination in 
normal and pathological states. The model 
results may be useful in the design of 
therapeutic procedures required for the safe 
and effective therapeutic use of a drug. 
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a)       b) 
  
 
c)       d) 
  
 
e)     
 
Figure 3: Effect of various parameters (a) diffusivity effect (b) metabolic rate effect (c) release rate effect (d) 
intraocular pressure effect (e) hydraulic conductivity effect on the drug concentration variation with time at the 
centre of retina.  A decrease in the release rate of drug decreases the drug concentration as evident from the 
curves in Fig.3(c).The curves in Fig.3(d) depict the variation in the drug concentration rate due to the change in 
the intraocular pressure. An elevated intraocular pressure as observed in the glaucomatous eyes, increases the 
drug concentration rate as observed from the graphs in Fig.3(d). Initially, the drug concentration rate increases 
and assumes its peak value at t=100 hrs. After that it begins to decay. The decay rate of retinal drug 
concentration is higher in the glaucomatous eyes. The change in the drug concentration at the centre of retina 
with time is affected by the hydraulic conductivity of the retina. A ten fold increase in the hydraulic conductivity, as 
observed in a pathological state of retinal detachment increases the concentration time variation. The drug decay 
rate is higher in the case of retinal detachment as more amount is swept away from the retinal surface due to 
increased effects of the convection and the drug may be eliminated with a faster rate.  
The curves in Fig.4(a)-(e) depict the drug concentration distribution along the centreline of vitreous body at t=100 
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a)       b) 
  
c)       d) 
  
e)        
 
Figure 4: Effect of various parameters (a) diffusivity effect (b) metabolic rate effect (c) release rate effect (d) 
intraocular pressure effect (e) hydraulic conductivity effect on the drug concentration distribution along the centre line 
of vitreous body at time t=100 hrs 
It is observed from the curves in Fig.4(a)  that the concentration of drug is maximum at the center of vitreous body and 
decreases towards the outer surface of the vitreous body. The concentration decays as the drug is transported across 
the vitreous body. The concentration of high diffusivity drugs is higher than that of low diffusivity drugs. An increase in 
the metabolic reaction rate constant enhances the consumption of drug which causes a decrease in the drug 
concentration, distributed along the centreline of vitreous body as is observed from the curves in Fig.4(b). The curves 
in Fig.4(c) shows that an decrease in the release rate of drug decreases the drug concentration along the centreline of 
vitreous body. The curves in Fig.4(d)-(e) show  the spatial variation  of drug concentration at time t=100 hrs along the 
centreline of vitreous body for some patho- physiological states: glaucoma and retinal detachment. It is seen from the 
curves in Fig.4(d)-(e) that the concentration of drug along the centreline of vitreous body is higher for glaucomatous 
and retinal detachment eyes as compared  to  that in normal eye. 
This indicates that with the increased convection to the vitreous the drug transport after intravitreal injection is 
enhanced and there is a sharp decrease in concentration reaching to the retinal surface. 
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Table 1: Definitions and explanations of terms /symbols  
 
Symbol Explanation Numerical value Reference





(sec/10*1 27 cm− large 
molecule) 
1 
rD  Diffusion coefficient in the retina /choroid  /sclera      sec/10*51.5 27 cm−  
12 
1D  Diffusion coefficient in the lens sec/10*83.1 26 cm−  
12 
pD  Diffusion coefficient in the aqueous humor sec/10*0.1 25 cm−  
12 
rl  Thickness of retina            0.324 cm 
12 
pl  Thickness of posterior chamber boundary layer            0.0040 cm 
12 
1l  Effective thickness of the lens 0.38±0.044 cm 
12 
R Radius of the vitreous body 0.72 cm 12 
H Height of the vitreous body 0.72 cm 12 
0b  Radius of the lens 0.36 cm 
12 
actR  Active transport term          
sec/10*7.5 6 cm−  
6 
pk  Hydraulic conductivity of the posterior chamber    vitreous body  interface           0.74 spacm ./
2  
6 
rk  Hydraulic conductivity of the RCS /vitreous          spacm ./10*5 210−  
 
6 
lk  Hydraulic conductivity of the lens/vitreous body interface                                       0.324 spacm ./
2  
6 




µ Viscosity of the vitreous humor         spa.10*4.14.3 4±  
16 
vp  Pressure of the vein down stream flow 9 mm Hg 
16 
ap  Pressure in the aqueous humor 15 mm Hg 
6 
M Initial loading of the drug 500µg 6 
K Rate constant for the drug  release 0.057 days 6 
V Volume of the  drug injection 500 µm 6 
B
Mk =1  
Metabolic rate constant 4,8,16 17 
1K  Release rate constant 1410*7.5 −− s  
6 
0c  Initial concentration in the vitreous body 33 /10*5 −− cmg  
1 
z Axial distance 0.8 cm 1 
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CONCLUSION   
The concentration of intravitreally injected 
drug at the centre of retina an along centreline 
of vitreous body is reduced as the metabolic 
reaction(consumption) rate and drug release 
rate constant increase in normal and diseased 
eyes. It is seen from the various curves in 
graphs that drug concentration decay rate in 
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